GMO/NGT: A memo from the French Embassy in the United States ignored by the government
In late April 2026, the French government supported the deregulation of GMOs produced using new techniques of genetic modification (GMO/NGT). A month earlier, however, the French Embassy in the United States had sent the government a memo detailing the situation in that country. Despite more than 140 marketing authorisations, only a few GMO/NGT are actually on the market there… but with significant patent-related issues. The situation described bears no resemblance to the promises made by multinational corporations or the European Commission.
Crispr/Cas9 : from patent disputes to the widespread use of GMOs
A dispute over patent rights to Crispr/Cas9 has been ongoing for several years between its main discoverers, universities and research institutes. To date, the outcome of this dispute and its impact on the Crispr/Cas9 economy remain unpredictable. Added to this is an ongoing dispute over Crispr applications between the parties to the main dispute and companies. Despite this, the widespread use of this tool for modifying living organisms, and the associated health, environmental and socio-economic consequences, seem inevitable.
Few micro-organisms modified by Crispr are already on the market
